Bacteriology. Mycology. Genova Diagnostics SAMPLE REPORT. Rare. Rare. Negative. Brown. Negative *NG. Negative

Similar documents
Bacteriology. Mycology. Patient: REDOX Biomedicine Co., Ltd. Referring Laboratory Attn Alan Ou 5F, No. 369, Song Jiang Road Taipei, Taiwan

Bacteriology. Mycology. Patient: SAMPLE PATIENT DOB: Sex: MRN: Rare. Rare. Positive. Brown. Negative *NG. Negative

Bacteriology. Mycology. Patient: SAMPLE PATIENT DOB: Sex: MRN: None. Rare. Negative. Brown. Negative *NG. Negative

Comprehensive Digestive Stool Analysis 2.0

COMPLETE DIGESTIVE STOOL ANALYSIS - Level 2

2200 GI Effects Comprehensive Profile Stool Interpretation At-a-Glance

TEST PATIENT. Date of Birth : 12-Jan-1999 Sex : M Collected : 25-Oct TEST DRIVE. Lab id :

COMPLETE DIGESTIVE STOOL ANALYSIS - Level 3

Interpretation At-a-Glance INFECTION INFLAMMATION INSUFFICIENCY IMBALANCE. GI Effects Comprehensive Profile - Stool. Patient: SAMPLE PATIENT

Interpretation At-a-Glance

Interpretation At-a-Glance INFECTION INFLAMMATION INSUFFICIENCY IMBALANCE RELATIVE ABUNDANCE GI Effects Comprehensive Profile - Stool.

Comprehensive Stool Analysis / Parasitology x3

Comprehensive Stool Analysis / Parasitology x3

Interpretation At-a-Glance Bacteriology. Parasitology

COMPLETE DIGESTIVE STOOL ANALYSIS - Level 3

COMPLETE DIGESTIVE STOOL ANALYSIS - Level 3+

COMPLETE DIGESTIVE STOOL ANALYSIS - (CDSA) Level 4

Comprehensive Stool Analysis / Parasitology x2

COMPLETE DIGESTIVE STOOL ANALYSIS - Level 5

TEST PATIENT. Date of Birth : 04-Jan-2002 Sex : M Collected : 26-Oct TEST STREET. TEST SUBURB VIC 3000 Lab id :

COMPLETE DIGESTIVE STOOL ANALYSIS - Level 4

INFECTION INFLAMMATION INSUFFICIENCY IMBALANCE

Laboratory report. Test: Leaky gut test. Sample material: stool. John Doe Main St 1 Anytown

COMPLETE DIGESTIVE STOOL ANALYSIS - Level 2

INFECTION INFLAMMATION INSUFFICIENCY IMBALANCE

Ever wonder what s really happening on the inside?

COMPLETE DIGESTIVE STOOL ANALYSIS - Level 3+

!Microbiology Profile, stool

Corporate Medical Policy

HAIR ELEMENTS. DOCTOR S DATA, INC. ADDRESS: 3755 Illinois Avenue, St. Charles, IL CLIA ID NO: 14D MEDICARE PROVIDER NO:

Comprehensive Stool Analysis / Parasitology x3

FECAL ANALYSIS IN THE DIAGNOSIS OF INTESTINAL DYSBIOSIS

!Microbiology Profile, stool

!Comprehensive Stool Analysis

!Comprehensive Parasitology,stool, x2

ROLE OF THE GUT BACTERIA

INTESTINAL MICROBIOTA EXAMPLES OF INDIVIDUAL ANALYSES

INTRODUCING YOUR GUT BACTERIA

Microbiology Profile, stool

Interpretive Guide INFECTION INFLAMMATION INSUFFICIENCY IMBALANCE. Infection Box Inflammation Box Insufficiency Box Imbalance Box

Clinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut

!Comprehensive Stool Analysis / Parasitology x1

Page: 1 of 7. Fecal Analysis in the Diagnosis of Intestinal Dysbiosis

!Comprehensive Parasitology,stool, x3

Complete Digestive Stool Analysis (CDSA)

Biomarkers of GI tract diseases. By Dr. Gouse Mohiddin Shaik

Comprehensive Stool Analysis / Parasitology x2

!Comprehensive Stool Analysis

Sequioa Education Systems, Inc. 1

Understanding probiotics and health

Summary of Product Characteristics

Lavanya Nutankalva,MD Consultant: Infectious Diseases

CANDIDIASIS AND LEAKY GUT PROTOCOLS

Dietary Fibres Soluble Fibres: can be.. Insoluble Fibres : can be..

Biacid: A EU approved natural growth promoter for Broilers

GI Effects Stool Profiles. Interpretive Guide

Intestinal Problems and "Whole-Body" Symptoms Gut The Intestinal Milieu

Module Four: The GI System Module Five: The Gut Microbiome. The GI System. LLiana Shanti, CN

Health Benefits of Prebiotic Dietary Fiber

P A T I E N T H A N D B O O K

!Comprehensive Stool Analysis / Parasitology x3

Saliva & Feces analysis

Diverticular Disease: Looking beyond fiber

Dysbiosis & Inflammation

Microbiome GI Disorders

Medical Policy. MP Fecal Analysis in the Diagnosis of Intestinal Dysbiosis

THE MISSING PIECE IN AUTISM DIAGNOSIS: COULD WE BE OVERLOOKING THE GUT MICROBIOME?

FIBOFIT IS Water soluble fiber

Module Outline. 1. Microbiome overview: getting a sense of the microbiome, research, what we know

Gut-Well Accession:

What is Dietary Fibre?

Gut-Well Accession:

FIBER HEALTH BENEFITS

The effect of probiotics on animal health: a focus on host s natural intestinal defenses

Fecal Analysis in the Diagnosis of Intestinal Dysbiosis

Optimising Gut Health. Using Comprehensive Microbiology Testing

Probiotics in the ICU. Who could benefit? Nadia J van Rensburg RD(SA) Groote Schuur Hospital, Cape Town

Support Guide. Introduction

Start calves off right... naturally!

Mark Manary MD. International Symposium on Understanding Moderate Malnutrition in Children for Effective Interventions

Alternative Nutritional Lab Tests. by Ronald Steriti, NMD, PhD

Fecal Analysis in the Diagnosis of Intestinal Dysbiosis

Digestion and Absorption

HMCL223 Clinical Diagnostic Techniques

Assessing Gut Issues: Short Chain Fatty Acids Elizabeth Redmond, PhD, MMSc, RD

Etiology, Assessment and Treatment

Ingestion Digestion- Absorption- Elimination

Probiotic. Prebiotics:

APPROACHES TO DIETARY THERAPY IN INFLAMMATORY BOWEL DISEASE

Lower Gastrointestinal Tract KNH 406

Dietary Fiber and its Influence on Gut Health

Digestive System. Why do we need to eat? Growth Maintenance (repair tissue) Energy

השפעת חיידקים פרוביוטיים

2/3/2011. Adhesion of Bifidobacterium lactis HN019 to human intestinal

Digestive Care Advisor Training #1. Digestion 101 & H.O.P.E.

PREBIOTIC MECHANISMS OF ACTION

The Gut Microbiome: 101 Justin Carlson University of Minnesota

The use of medium chain fatty acids as alternatives to antibiotic use in pigs

Mrs. -TESTER, Tester (Reference: ) Date of report: Personalized Report

THE LIVER AND THE GUT

Transcription:

Completed: November 2010 Genova Diagnostics eceived: October 2010 Collected: October 2010 oute Number:7 4.2 0.9-26.8 U/g 0.9 0.2-3.3 mg/g 0.8 1.3-8.6 micromol/g 42.7 1.3-23.7 mg/g 1.7 0.2-3.5 mg/g are 1.8 0.2-8.8 mg/g are 47.1 2.6-32.4 mg/g 13.8 >= 13.6 micromol/g Bacteriology 2.2 774 6.5 64.5 19.3 >= 2.5 micromol/g 337-4,433 U/g 6.1-7.9 44.5-72.4 % <= 32.1 % Mycology Lactobacillus species *NG Escherichia coli 4+ Bifidobacterium 3+ alpha haemolytic treptococcus NP 2+ treptococcus agalactiae gp B NP 4+ Coag. negative taphylococcus NP 1+ Citrobacter braakii PP 4+ Kluyvera cryocrescens NP 1+ Candida albicans NP 1+ accharomyces cerevisiae NP 1+ 15.9 10.8-33.5 % Brown *NG

Page 2 In ange Out of ange Lab Comments ENI': All yeast, add'l bacteria The performance characteristics of all assays have been verified by Genova Diagnostics, Inc. Unless otherwise noted with as cleared by the U.. Food and Drug Administration, assays are For esearch Use Only. Commentary is provided to the practitioner for educational purposes, and should not be interpreted as diagnostic or treatment recommendations. Diagnosis and treatment decisions are the responsibility of the practitioner. The eference ange is a statistical interval representing 95% or 2 tandard Deviations (2.D.) of the reference population. One tandard Deviation (1.D.) is a statistical interval representing 68% of the reference population. Values between 1 and 2.D. are not necessarily abnormal. Clinical correlation is suggested. (ee example below) Human microflora is influenced by environmental factors and the competitive ecosystem of the organisms in the GI tract. Pathological significance should be based upon clinical symptoms and reproducibility of bacterial recovery. Triglycerides constitute the major component of dietary fat and are normally broken down by pancreatic lipase into glycerol and free fatty acids. Triglycerides are within the reference range, indicating adequate fat digestion or a lack of dietary fat. Chymotrypsin is within the reference range. Chymotrypsin is a key pancreatic enzyme that catalyzes protein digestion. Thus, the fecal level is a measure of proteolytic activity and a marker for pancreatic enzyme output as a whole. A value within the reference range suggests normal enzyme production. Levels are also influenced by transit time, such that faster transit results in higher fecal levels.

Valerate, iso-valerate and iso-butyrate are "putrefactive" short chain fatty acids produced when anaerobic bacteria ferment undigested protein. While low levels of hort Chain Fatty Acids are statistically significant, the clinical relevance is doubtful. Low Putrefactive CFAs appear to be a variant of normal. Elevated amounts of meat and/or vegetable fibers were seen in the stool. High concentrations of these fibers are normally absent from the feces. Increased amounts are indirect indicators of maldigestion due to hydrochloric acid/pepsin insufficiency, pancreatic enzyme insufficiency, or inadequate mastication of food. Long chain fatty acids (LCFAs) are broken down by pancreatic lipase from dietary triglycerides and are normally readily absorbed by the intestinal mucosa. Elevated levels in the stool suggest fat malabsorption in the small bowel, possibly resulting from bile salt insufficiency, excessive dietary fat, or inflammation within the intestinal mucosa. Cholesterol is within the reference range, suggesting adequate absorption of cholesterol by the small intestine or low dietary intake. Phospholipids are normal. 50% of phospholipids are derived from bile, with 25% coming from mucosal desquamation and 25% from dietary sources. Nearly 85% of intestinal phospholipids are absorbed. Normal levels of fecal phospholipids indicate average dietary fat intake and adequate digestion/ absorption. The total fecal fats are calculated as the sum of fecal triglycerides, phospholipids, cholesterol and long chain fatty acids (LCFAs). Elevated levels reflect pancreatic insufficiency (expect elevated triglycerides), malabsorption (expect elevated long chain fatty acids or cholesterol), or both. Beneficial (Total) short chain fatty acids (CFAs) are acetate, propionate and n-butyrate. They are the end products of anaerobic microbial fermentation of dietary fiber. Levels thus reflect the concentration of intestinal flora as well as soluble fiber in the diet. These beneficial CFAs are crucial to the health of the intestine, serving as sources of fuel for the cells and the rest of the body. They also help to regulate the fluid balance in the colon. n-butyrate is the most important of the beneficial CFAs, and is the primary energy source for colonic epithelial cells. Adequate amounts are necessary for the healthy metabolism of the colonic mucosa, and have been shown to have protective effects against colorectal cancers. Low levels of n-butyrate are associated with a higher risk of colon cancer and ulcerative colitis. Beta-glucuronidase is within the reference range. This is an inducible enzyme, produced by E. coli and anaerobes Bacteroides, and Clostridia. Its activity reverses the detoxication of compounds processed in the hepatic Phase II glucuronidation pathway (including many pharmaceuticals, carcinogens, bile acids, and estrogen). Fecal ph is within the reference range. The ph of the stool is a reflection of several factors in the GI tract, such as gastric acid, pancreatic bicarbonate, short chain fatty acids, ammonia, bile, organic acids, and acids produced by beneficial flora. Proper levels enhance colonization by beneficial flora, deter possible pathogens, promote normal digestive processes, and promote CFA production. The CFA Distribution reflects the relative proportions of the beneficial CFAs (n-butyrate, propionate, and acetate), thus providing an indirect measure of balance among the anaerobic organisms in the colon. ufficient amounts of E. coli appear to be present in the stool. However, Lactobacilli and Bifidobacteria were found in lower than optimal levels. Ample amounts of E. coli have been associated with a balanced gut flora. The "friendly bacteria", Lactobacilli and Bifidobacteria, are important for gastrointestinal function, as they are involved in vitamin synthesis, natural antibiotic production, immune defense, digestion, detoxification of pro-carcinogens and a host of other activities. Ideally, levels of Lactobacillus and E. coli should be 2+ or greater. Bifidobacteria being a predominate anaerobe should be recovered at levels of 4+. There is no detection of fecal lactoferrin. This indicates no active intestinal inflammation. However, non-inflammatory diarrhea caused by irritable bowel syndrome, small intestinal viral infections, non-invasive parasitic infections, or other etiologies may still be present even in the absence of lactoferrin.

Prescriptive Agents CITOBACTE BAAKII I Amox./Clavulanic Acid Ampicillin Cephalothin Ciprofloxacin Tetracycline Trimethoprim/ulfa I Indicates susceptibility to prescriptive agents Indicates intermediate susceptibility to prescriptive agents Indicates resistance to prescriptive agents Natural Agents CITOBACTE BAAKII Berberine Oregano Plant Tannins Prescriptive Agents: Microbial testing has been performed in vitro to determine antibiotic sensitivity and resistance at standard dosages. Prudent use of antimicrobials requires knowledge of appropriate blood or tissue levels of those agents. Antibiotics that appear in the "" (susceptible) column are more effective at inhibiting the growth of this organism. Antibiotics that appear in the "I" (intermediate) column are partially effective at inhibiting the growth of this organism. Antibiotics that appear in the "" (resistant) column allow continued growth of the organism in vitro and are usually less effective clinically. Inappropriate use of antibacterials often results in the emergence of resistance. Natural Agents: In this assay, "inhibition" is defined as the reduction level on organism growth as a direct result of inhibition by a natural substance. The level of inhibition is an indicator of how effective the natural substance was at limiting the growth of an organism in an in vitro environment. High inhibition indicates a greater ability by the natural substance to limit growth, while a lesser ability to limit growth. These natural products should be considered investigational in nature and not be viewed as standard clinical treatment substances. Uva-Ursi 63 Zillicoa treet Asheville, NC 28801-1074

CANDIDA ALBICAN Azole Antifungals I Fluconazole <=0.125 Itraconazole =0.25 Ketoconazole =0.125 I CANDIDA ALBICAN Nystatin CANDIDA ALBICAN Berberine Caprylic Acid Indicates susceptibility to prescriptive agents Indicates intermediate susceptibility to prescriptive agents Indicates resistance to prescriptive agents Non-absorbed Antifungals Natural Antifungals Azole Antifungals: Microbial testing has been performed in vitro to determine antifungal sensitivity and resistance at standard dosages. Prudent use of antimicrobials requires knowledge of appropriate blood or tissue levels of those agents. Antifungals that appear in the "" (susceptible) column are more effective at inhibiting the growth of this organism. Antifungals that appear in the "I" (intermediate) column are partially effective at inhibiting the growth of this organism. Antifungals that appear in the "" (resistant) column allow continued growth of the organism in vitro and are usually less effective clinically. Inappropriate use of antifungals often results in the emergence of resistance. Nystatin and Natural Antifungals: In this assay, "inhibition" is defined as the reduction level on organism growth as a direct result of inhibition by a natural substance. The level of inhibition is an indicator of how effective the natural substance was at limiting the growth of an organism in an in vitro environment. High Inhibition indicates a greater ability by the natural substance to limit growth, while Low Inhibition a lesser ability to limit growth. In accordance with laboratory guidelines for reporting sensitivities, results for Nystatin are now being reported with natural antifungals in this category. Garlic Undecylenic Acid Plant tannins Uva-Ursi 63 Zillicoa treet Asheville, NC 28801-1074

Azole Antifungals ACCHAOMYCE CEEVIIAE I Fluconazole =4.0 Itraconazole =2 Ketoconazole =0.5 I Indicates susceptibility to prescriptive agents Indicates intermediate susceptibility to prescriptive agents Indicates resistance to prescriptive agents Non-absorbed Antifungals ACCHAOMYCE CEEVIIAE Nystatin Natural Antifungals ACCHAOMYCE CEEVIIAE Berberine Caprylic Acid Garlic Azole Antifungals: Microbial testing has been performed in vitro to determine antifungal sensitivity and resistance at standard dosages. Prudent use of antimicrobials requires knowledge of appropriate blood or tissue levels of those agents. Antifungals that appear in the "" (susceptible) column are more effective at inhibiting the growth of this organism. Antifungals that appear in the "I" (intermediate) column are partially effective at inhibiting the growth of this organism. Antifungals that appear in the "" (resistant) column allow continued growth of the organism in vitro and are usually less effective clinically. Inappropriate use of antifungals often results in the emergence of resistance. Nystatin and Natural Antifungals: In this assay, "inhibition" is defined as the reduction level on organism growth as a direct result of inhibition by a natural substance. The level of inhibition is an indicator of how effective the natural substance was at limiting the growth of an organism in an in vitro environment. High Inhibition indicates a greater ability by the natural substance to limit growth, while Low Inhibition a lesser ability to limit growth. In accordance with laboratory guidelines for reporting sensitivities, results for Nystatin are now being reported with natural antifungals in this category. Undecylenic Acid Plant tannins Uva-Ursi 63 Zillicoa treet Asheville, NC 28801-1074